BioSpace News Archive

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has entered into exclusive agreement with UpScript, LLC in which UpScript will serve as the exclusive online telehealth provider for gammaCore Sapphire™ CV (nVNS). Patients can access telehealth consults for the gammaCore Sapphire™ CV product effective immediately by visiting gammaCore.com or directly through getgammaCore.com. “T

Emergent BioSolutions today announced its strong support for the new Canadian national consensus guidelines for naloxone prescribing by pharmacists published in the Canadian Pharmacists Journal for aiming to bring clarity and consistency to naloxone prescribing, which may ultimately help reverse more opioid poisonings until medical help arrives.

Clinical research, forensic and anti-doping toxicology laboratories facing the challenges of analyzing increasing numbers of analytes in biological matrices, can now easily and rapidly optimize their liquid chromatography-mass spectrometry (LC-MS) methods for targeted screening and quantification.

Ontario Power Generation (OPG), its subsidiary Laurentis Energy Partners (Laurentis), BWXT ITG Canada Inc. and its affiliates (BWXT) are making significant progress toward the production of molybdenum-99 (Mo-99) at OPG’s Darlington Nuclear Generating Station.

DisperSol Technologies LLC announced today that its Board of Directors has appointed David S. Snyder as its Chief Financial Officer effective October 1, 2020. “David Snyder is a highly accomplished pharmaceutical finance executive with extensive experience in managing the finances and growth of life science businesses,” said Dr. Edwar

The board of directors of Pfizer Inc. (NYSE:PFE) declared a 38-cent fourth-quarter 2020 dividend on the company’s common stock, payable December 1, 2020, to holders of the Common Stock of record at the close of business on November 6, 2020. The fourth-quarter 2020 cash dividend will be the 328 th consecutive quarterly dividend paid by Pfizer.

Notable, a functional precision medicine company, and myTomorrows, an integrated platform that links patients with an unmet medical need to treatments in development worldwide, are proud to announce their partnership.

KSQ Therapeutics to Present New Data from its USP1 Inhibitor Program at Upcoming EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics CAMBRIDGE, Mass.--( BUSINESS WIRE )-- KSQ® Therapeutics, a biotechnology company using its proprietary CRISPRomics® discovery platform to systematically screen the whole genome to identify optimal gene targets for oncology and autoimmune disease, announced it will present new data from its USP1 inhibitor pr

Leap Therapeutics, Inc. announced that the FDA has granted Fast Track designation to DKN-01 for the treatment of patients with gastric and gastroesophageal junction adenocarcinoma whose tumors express high Dickkopf-1 protein, following disease progression on or after prior fluoropyrimidine- and platinum- containing chemotherapy and if appropriate, human epidermal receptor growth factor /neu-targeted therapy.

Project includes funding for preliminary engineering work on facility to manufacture over 1 billion doses per year